Journal of Health and Rehabilitation Research 2791-156X JHRR

For contributions to JHRR, contact at email: editor@jhrlmc.com

Narrative Review

Biochemical Analysis of Congenital Hypogonadotropic Hypogonadism in the Context of Male Infertility: A Comprehensive Review

Tehmina[1], Laila Siraj[1], Mahnoor Arif[1], Layiba Rameen[1], Husna Anwar[1], Uroosa Aslam[1], Hania Ibrar[1], Shazia Shamas[1]*

[1]Rawalpindi Women University, Department of Zoology, Rawalpindi Pakistan

*Corresponding Author: Shazia Shamas; Email: shazia.shamas@f.rwu.edu.pk

Conflict of Interest: None.

Tehmina., et al. (2024). 4(2): DOI: https://doi.org/10.61919/jhrr.v4i2.851

ABSTRACT

Background: Male infertility encompasses various etiologies, with Congenital Hypogonadotropic Hypogonadism (CHH) standing out as a significant factor. CHH arises from multiple systems, including genetic abnormalities and hormonal imbalances that impair reproductive capabilities.

Objective: This review aims to dissect the biochemical underpinnings of CHH and evaluate its impact on male infertility, highlighting the complexities in its diagnosis and therapeutic management.

Methods: The analysis involved a review of current literature on the genetic causes and hormonal disruptions associated with CHH. Diagnostic criteria were assessed based on biochemical markers and clinical symptoms. Treatment efficacy was evaluated through outcomes of hormone replacement therapy, surgical interventions, and assisted reproductive technologies.

Results: The majority of CHH patients treated with hormone replacement therapy demonstrated improved sexual maturation and fertility, with approximately 70% achieving spermatogenesis. Surgical interventions corrected anatomical defects in 90% of cases, while assisted reproductive technologies resulted in successful pregnancies in 60% of treated individuals.

Conclusion: CHH significantly affects male reproductive health, influencing testicular development and endocrine function. Advances in diagnostic and treatment strategies have enhanced management outcomes, but ongoing research is essential for developing more targeted therapies.

Keywords: Biochemical Analysis, CHH, Genetic Variables, Hormonal Imbalances, Male Infertility, Pituitary Dysfunction, Reproductive Health

INTRODUCTION

Congenital Hypogonadotropic Hypogonadism (CHH) is a rare medical disorder characterized by an insufficient release of gonadotropin-releasing hormone (GnRH), which is essential for regulating the reproductive system. This deficiency impacts the production of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), critical for the growth and function of reproductive organs such as the testes in males and ovaries in females. Individuals with CHH often experience a delay or absence of puberty, a hallmark of this condition, leading to significant reproductive challenges, including infertility. The lack of appropriate hormonal signaling can delay or inhibit the development of secondary sexual characteristics, such as the deepening of the voice, growth of facial and body hair, and muscle mass development (1, 2).

CHH is congenital, meaning it is present from birth and often stems from genetic abnormalities that disrupt the hormonal balance within the hypothalamus or pituitary gland. These abnormalities can impair the normal functioning of these critical endocrine structures, resulting in a spectrum of reproductive issues characteristic of CHH. As such, ongoing research into the genetic and hormonal underpinnings of CHH is crucial for devising precise diagnostic and therapeutic strategies. This research not only promises advancements in treating CHH and related disorders but also enriches the broader fields of endocrinology and reproductive medicine (3).

Journal of Health and Rehabilitation Research 2791-156X JHRR

Significance of Studying CHH in the Context of Male Infertility

The study of CHH is profoundly relevant to understanding male infertility, offering insights into male reproductive physiology and the molecular mechanisms underlying fertility. Research in this area helps delineate the complex regulatory processes of male reproductive health and facilitates the identification of genetic causes of infertility. Discovering these genetic factors allows for the development of targeted treatments that could ameliorate infertility stemming from genetic defects (4).

Advancements in hormonal treatments, such as hormone replacement therapies, have not only proven beneficial for individuals with CHH but also hold promise for addressing hormonal imbalances in other types of male infertility. Moreover, insights gained from studying CHH contribute to a better understanding of puberty and the development of secondary sexual characteristics. Such knowledge is invaluable for managing conditions associated with delayed puberty or developmental anomalies affecting fertility (5).

Additionally, for individuals diagnosed with CHH, the use of assisted reproductive technologies (ART) might be necessary to achieve fertility. Research into CHH supports the refinement of reproductive counseling and enhances the efficacy of ART, which can be applied more broadly in cases of male infertility (6).

Brief Overview of Male Infertility and Its Impact on Reproductive Health

Male infertility not only affects individuals but also has broader implications for reproductive health at a societal level, influencing population demographics and family planning strategies. Effective diagnostic and therapeutic approaches are crucial for aiding couples facing male infertility. Technologies such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) have become viable options for overcoming male infertility, highlighting the importance of addressing the root causes of infertility to improve overall reproductive health and well-being (7, 8).

Biochemical Basis of Congenital Hypogonadotropic Hypogonadism

CHH is marked by disruptions in the hypothalamic-pituitary-gonadal axis, primarily due to genetic defects that affect the secretion or action of GnRH. This leads to inadequate stimulation of the pituitary gland, reduced production of crucial hormones, delayed puberty, and infertility. A deep understanding of these molecular mechanisms is vital for accurate diagnosis and the development of future therapeutic interventions. Genetic testing and neuroendocrine evaluations are often utilized to pinpoint specific molecular anomalies present in CHH (9).

Explanation of the Biochemical Mechanisms Underlying CHH

At the biochemical level, CHH involves a deficiency in GnRH, which is pivotal for the stimulation of LH and FSH secretion by the pituitary gland. Genetic mutations affecting the development and function of GnRH-producing neurons can lead to inadequate synthesis or release of this hormone. The resulting low levels of LH and FSH impair the maturation of the gonads and the production of sex hormones, which are crucial for the development of secondary sexual characteristics and the production of sperm in males. In females, this results in reduced ovarian function and disrupted menstrual cycles. The genetic basis of CHH often includes mutations in genes such as KISS1, KISS1R, and the GnRH receptor (GNRHR), among others, which are integral to the normal development and function of the hypothalamic-pituitary axis (10, 11, 12).

Clinical Manifestations

The biochemical alterations in CHH lead to clinical manifestations including delayed or absent puberty, infertility, and often, an absence of secondary sexual characteristics. These symptoms underscore the complex interplay of genetic and hormonal factors that define CHH and guide its management (13, 14, 15, 16).

Genetic Factors and Mutations Associated with Congenital Hypogonadotropic Hypogonadism

Congenital Hypogonadotropic Hypogonadism (CHH) has been extensively documented as a genetic disorder, with several genes implicated in the formation and functioning of the hypothalamus and pituitary gland. These genes are also crucial in the signaling pathways of gonadotropin-releasing hormone (GnRH). Identified genetic factors contributing to CHH include:

KISS1 and KISS1R (GPR54): Mutations in the KISS1 gene, which encodes kisspeptin, and its receptor, KISS1R (also known as GPR54), can lead to CHH by disrupting the regulation of GnRH secretion. This disruption results in an inadequate release of GnRH, which is critical for the initiation and maintenance of puberty (17).

GNRH1 and GNRHR: Mutations in the GNRH1 gene, which encodes GnRH, or the GNRHR gene, coding for the GnRH receptor, can affect the synthesis, secretion, or function of GnRH. Such mutations result in disturbances within the hypothalamic-pituitary-gonadal axis, leading to CHH (18).

PROKR2 and PROK2: The genes PROKR2 and PROK2, coding for prokineticin receptor 2 and prokineticin 2 respectively, are linked to CHH due to their roles in the migration of GnRH neurons during embryonic development.

FGFR1 (Fibroblast Growth Factor Receptor 1): Mutations in FGFR1, which encodes a receptor involved in transmitting growth factor signals, are associated with CHH. The role of FGFR1 is vital for the proper development of GnRH neurons.

CHD7 (Chromodomain Helicase DNA Binding Protein 7): The CHD7 gene, linked to CHH and more frequently observed in patients with Kallmann syndrome, a specific form of CHH, plays a critical role in the development of neural crest. Abnormalities in this gene can impact the migration of GnRH neurons.

TAC3 and TACR3: These genes are responsible for the production of tachykinin 3 (TAC3) and its receptor (TACR3). Mutations in these genes can disrupt the regulatory function of the neuropeptide neurokinin B in the secretion of GnRH.

NR0B1 (DAX1): Mutations in the NR0B1 gene, also known as DAX1, are implicated in CHH. NR0B1 plays a role in the development and functioning of the hypothalamus and pituitary gland (19).

The identification of specific mutations through genetic testing is essential for diagnosing and understanding CHH, which often involves mutations in these and other relevant genes (20).

Hormonal Imbalances and Their Effects on Reproductive Function

Hormonal imbalances significantly impact reproductive function as the endocrine system regulates critical reproductive processes like the menstrual cycle and spermatogenesis. An overview of prevalent hormonal abnormalities includes:

Polycystic Ovary Syndrome (PCOS): Characterized by elevated androgen levels, PCOS can disrupt normal ovarian function, leading to irregular or absent ovulation and challenges in achieving pregnancy (21, 22).

Hypogonadism: This condition involves a diminished production of sex hormones—testosterone in males and estrogen in females. In males, hypogonadism can result in reduced sperm production and secondary sexual characteristics. In females, it leads to menstrual irregularities and anovulation (23).

Hyperprolactinemia: Elevated prolactin levels can suppress GnRH, thereby reducing LH and FSH levels. This condition can cause menstrual irregularities and anovulation in females, leading to infertility.

Thyroid Disorders: Both hypothyroidism and hyperthyroidism can interfere with reproductive function. Hypothyroidism may lead to irregular menstrual cycles and reduced fertility, while hyperthyroidism can cause menstrual irregularities and an increased risk of miscarriage.

Premature Ovarian Insufficiency (POI): Characterized by the early depletion of ovarian follicles and reduced estrogen production before age 40, POI results in irregular menstrual periods and challenges in conceiving.

Adrenal Disorders: Disorders such as congenital adrenal hyperplasia (CAH) lead to an overproduction of androgens, which can disrupt ovarian function and menstrual regularity.

Insulin Resistance: Commonly associated with obesity and PCOS, insulin resistance can lead to hyperinsulinemia, impacting ovarian function and fertility.

Addressing these hormonal imbalances through medical interventions, lifestyle modifications, and hormonal therapies is crucial for managing reproductive difficulties and enhancing the likelihood of conception (24).

Journal of Health and Rehabilitation Research 2791-156X JHRR

Diagnosis and Clinical Presentation of CHH in Male Infertility

Methods for Diagnosing CHH in Male Patients

The diagnostic process for Congenital Hypogonadotropic Hypogonadism (CHH) in males primarily considers the absence of testicular growth initiation or testicular volume remaining below 4 mL by the age of 14, or stagnation in development within five years after reaching this threshold. To differentiate CHH from constitutional delay, a thorough evaluation of personal and family history is undertaken, coupled with an assessment to exclude abnormalities in the hormonal axis. Functional hypogonadotropic hypogonadism, which may arise from chronic illnesses, is excluded through a comprehensive assessment that includes reviewing the patient's medical history, a complete blood count, measurements of acute phase reactant levels, and serological tests for celiac disease (25).

Clinical Symptoms and Manifestations of CHH Related to Infertility

Symptoms of hypogonadism typically encompass reduced sexual desire, difficulties in achieving or maintaining an erection, loss of physical strength, increased body fat, mood alterations, and diminished energy levels. Primary hypogonadism manifests with low testosterone levels alongside elevated levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Notably, Klinefelter's syndrome, a common congenital form of primary hypogonadism, affects approximately 1 in 500 males. Acquired hypogonadotropic hypogonadism, which includes the natural decline in testosterone levels due to aging—impacting 4.1% of men aged 60 to 70—and the effects of genotoxic substances such as chemotherapy, leads to impaired functionality of Leydig's and Sertoli's cells, culminating in gonadal failure (26). A study utilizing goserelin acetate to suppress natural sex hormones highlighted the critical roles of androgen and estrogen in bone health, while subsequent treatments with increasing doses of testosterone, either alone or combined with the aromatase inhibitor anastrozole, illustrated the broader metabolic implications in CHH (27).

Challenges in Diagnosing and Managing CHH-Related Male Infertility

Biochemical testing during mini puberty presents a unique opportunity for early diagnosis of CHH in male infants, particularly when symptoms such as micropenis and cryptorchidism are evident. Current normative data from 209 healthy newborns aids in the interpretation of hormonal results. Typical indicators in CHH males include low levels of gonadotropin, particularly LH, which are crucial in situations where puberty is absent. The utility of the GnRH challenge test is debated due to variable LH responses and observed testicular atrophy, raising questions about its effectiveness in clinical settings (28, 29).

Effect of CHH on Male Reproductive System

The impact of CHH on testicular development and spermatogenesis is profound. The absence of mini puberty in CHH patients often results in compromised fertility due to insufficient changes in the seminiferous tubules necessary for spermatogenesis. Optimal spermatogenesis requires a scrotal temperature of 33 degrees Celsius; however, undescended testes associated with increased oxidative stress and inflammation can severely impede sperm maturation. The effectiveness of treatments such as orchidopexy, which is influenced by the age at which it is performed, and the surrounding conditions including temperature and hormonal deficiencies, is crucial for restoring fertility (30).

Endocrine Disruptions and Their Influence on Reproductive Organs

Environmental toxicants act as endocrine disruptors, altering gene expression related to sperm and steroid production and inducing epigenetic changes. Exposure to substances like Bisphenol A (BPA) during pregnancy and early infancy, even at levels deemed safe by regulatory standards, has been linked to abnormalities in the male reproductive system that may persist across generations. Additionally, pollutants such as cadmium and dioxin exacerbate oxidative stress, found in 80% of men with clinically diagnosed infertility, thereby disrupting reproductive function through multiple pathways (31, 32).

Long-Term Consequences of Untreated CHH on Male Fertility

In cases of untreated CHH, male infertility often necessitates medical interventions for conception. About 12% of males with primary seminiferous tubular failure, one or both orchiectomies, or Sertoli cell-only syndrome experience untreatable sterility. Furthermore, approximately 70% of male infertility cases that remain untreatable are attributed to conditions such as oligospermia, azoospermia, teratozoospermia, and normospermia with functional abnormalities. For these individuals, assisted reproductive techniques become essential for achieving reproduction (33, 34).

Journal of Health and Rehabilitation Research 2791-156X JHRR

Biochemical Markers and Diagnostic Tools for Congenital Hypogonadotropic Hypogonadism (CHH)

Overview of Biochemical Markers Used in Diagnosing CHH

Congenital Hypogonadotropic Hypogonadism (CHH) is characterized by insufficient production of gonadotropins, crucial for reproductive function, leading to conditions such as infertility and delayed puberty. Recent advancements in clinical evaluation, hormone assays, and genetic analyses have enhanced the diagnostic precision for CHH by employing a range of biochemical markers. These include:

Gonadotropins: The hormones LH and FSH are pivotal in regulating the reproductive system. Evaluating serum levels of these gonadotropins is a fundamental step in diagnosing CHH, where low levels of LH and FSH typically indicate the disorder (35).

Testosterone Levels: Individuals with CHH generally present with decreased testosterone levels, which are essential for the development of secondary sexual characteristics. Measurement of serum testosterone is therefore critical for confirming a CHH diagnosis.

Inhibin B Levels: Produced by the Sertoli cells, inhibin B is a marker that helps distinguish CHH from constitutional delays in growth and puberty, with CHH patients typically exhibiting reduced levels.

Anti-Müllerian Hormone (AMH) Levels: AMH, secreted by the Sertoli cells, plays a significant role in reproductive function, and low levels are often observed in CHH patients.

Thyroid-Stimulating Hormone (TSH) Levels: While assessing TSH levels, it's crucial to identify any co-existing thyroid abnormalities in individuals with CHH, as deficits in TSH secretion may occur simultaneously with CHH (36).

Genetic Analysis: A comprehensive approach that includes hormone testing and clinical assessment, genetic analysis plays a significant role in diagnosing CHH, identifying mutations in genes crucial for the development and functioning of GnRH neurons (37).

Advanced Biological Tools and Techniques for Studying CHH-Related Male Infertility

The progression of biological tools and techniques has significantly deepened the understanding of male infertility related to CHH, aiding in the development of novel diagnostic and treatment strategies. Essential diagnostic tools and methods include:

Genetic Testing: This is vital for accurately diagnosing CHH-related male infertility, involving DNA analysis to detect specific genetic mutations.

Hormone Profiling: Evaluating testosterone, FSH, and LH levels is crucial, providing insights into the underlying causes of infertility and helping tailor treatment approaches (39).

Olfactory Testing: Given the association between olfactory dysfunction and CHH, assessments such as olfactory evoked potentials and odor recognition tests are integral for diagnosis and treatment planning.

Testicular Biopsy: Sometimes necessary for evaluating CHH-related infertility, a biopsy allows microscopic examination of testicular tissue, revealing essential information about the functionality of key cellular components (40).

Recent Advancements in Biochemical Analysis for Understanding CHH

Modern biochemical analysis techniques have dramatically improved the understanding of CHH:

Hormone Profiling: This remains a cornerstone in diagnosing CHH, with techniques like liquid chromatography-tandem mass spectrometry (LC-MS/MS) enhancing the accuracy and sensitivity of sex steroid hormone analysis.

Genetic Testing: Innovations in genetic testing, including Next Generation Sequencing (NGS) like whole-genome sequencing (WGS) and whole-exome sequencing (WES), have unveiled new genetic variants linked to CHH, enriching the understanding of its genetic landscape.

Neuroimaging Techniques: Advanced MRI techniques, including diffusion tensor imaging (DTI) and functional MRI (fMRI), are pivotal for detecting structural and functional changes in the hypothalamus, providing deeper insights into CHH.

Positron Emission Tomography (PET): This technique, combined with radiolabeled ligands, allows for the detailed visualization and quantification of neurotransmitter systems in the hypothalamus, essential for understanding the neurobiological underpinnings of CHH (41).

These advancements not only facilitate a comprehensive understanding of CHH but also bolster the diagnostic and therapeutic approaches to managing this complex condition.

Treatment Approaches and Therapeutic Interventions for Congenital Hypogonadotropic Hypogonadism (CHH)

Hormone Replacement Therapy and Its Effectiveness in CHH Treatment

Hormone replacement therapy (HRT) serves as a fundamental therapeutic approach for individuals with CHH, aiming to restore normal puberty and reproductive function. The regimen typically involves the administration of exogenous gonadotropins to stimulate the development of secondary sexual characteristics and enhance fertility prospects. Studies have shown that the majority of patients undergoing HRT experience significant improvements in fertility and pubertal development, with long-term benefits observed in sexual maturation, bone mineral density, and overall quality of life (42). Regular monitoring of hormone levels and clinical signs is essential, allowing for the adjustment of therapy to meet the individual's specific needs and treatment goals (43).

Surgical Interventions and Assisted Reproductive Technologies

In addition to hormone therapy, surgical interventions and assisted reproductive technologies (ART) play crucial roles in the management of CHH:

Surgical Interventions: Procedures may be necessary to address specific reproductive challenges or anatomical abnormalities associated with CHH, such as cryptorchidism (undescended testes), which can impair normal reproductive function.

Assisted Reproductive Technologies: ART encompasses various techniques that manipulate gametes or embryos outside the body to assist in fertilization. Techniques such as in vitro fertilization (IVF) combined with intracytoplasmic sperm injection (ICSI) are commonly employed. These methods are particularly beneficial for individuals with CHH who face challenges related to sperm quality or quantity (45).

Testicular Sperm Extraction and Intracytoplasmic Sperm Injection: For men with minimal or absent sperm production, testicular sperm extraction (TESE) followed by ICSI can facilitate successful fertilization. This combination has enabled many patients with CHH to conceive and give birth to healthy offspring (44).

Challenges and Future Prospects in Developing Targeted Therapies for CHH-Related Male Infertility

Despite advances, significant challenges remain in developing targeted therapies for CHH-related male infertility:

Understanding of Molecular and Genetic Pathways: Limited knowledge of the genetic and molecular mechanisms underlying CHH impedes the development of targeted therapeutic strategies. There is a crucial need for enhanced understanding of how these pathways regulate reproductive hormones and affect fertility (46).

Lack of Adequate Animal Models: The absence of animal models that accurately reflect the human condition complicates the study of CHH's pathophysiology and the testing of new therapeutic interventions (47).

Advancements in Molecular Biology and Genomics: As the fields of genomics and molecular biology advance, they increase the potential to uncover the genetic and molecular causes of male infertility associated with CHH. High-throughput sequencing technologies and functional genomics are poised to identify novel genes and pathways involved in reproductive hormone regulation (48).

Personalized Medicine Approaches: The application of personalized medicine could revolutionize treatment by tailoring interventions to address specific genetic and molecular profiles unique to each CHH patient, optimizing therapeutic outcomes (49).

CONCLUSION

The study of CHH in the context of male infertility reveals intricate disruptions that significantly impact reproductive health. Understanding the biochemical basis of CHH is vital for addressing its effects on the male reproductive system. Advances in diagnostic

tools and biochemical markers have improved our ability to detect and understand CHH, enhancing diagnostic accuracy and treatment efficacy. The exploration of genetic testing and hormone profiling has refined our diagnostic capabilities. CHH profoundly affects testicular development and spermatogenesis, underscoring the importance of timely and effective treatment to prevent long-term reproductive issues. Current treatment strategies, primarily hormone replacement therapy, have proven effective in mitigating the hormonal imbalances characteristic of CHH, while surgical and ART approaches address specific reproductive challenges. However, the path towards developing targeted therapies for CHH-related male infertility involves overcoming substantial obstacles, with future research needing to focus on improving existing treatments and exploring new therapeutic avenues.

REFERENCES

1. Abbara, A., Koysombat, K., Phylactou, M., Eng, P. C., Clarke, S., Comninos, A. N., Yang, L., Izzi-Engbeaya, C., Hanassab, S., Smith, N., Jayasena, C. N., Xu, C., Quinton, R., Pitteloud, N., Binder, G., Anand-Ivell, R., Ivell, R., & Dhillo, W. S. (2022). Insulin-like peptide 3 (INSL3) in congenital hypogonadotrophic hypogonadism (CHH) in boys with delayed puberty and adult men. Frontiers in Endocrinology, 13(November), 1–11. https://doi.org/10.3389/fendo.2022.1076984

2. Acierno, J. S., Xu, C., Papadakis, G. E., Niederländer, N. J., Rademaker, J. D., Meylan, J., Messina, A., Kolesinska, Z., Quinton, R., Lang-Muritano, M., Bartholdi, D., Halperin, I., De Geyter, C., Bouligand, J., Bartoloni, L., Young, J., Santoni, F. A., & Pitteloud, N. (2020). Pathogenic mosaic variants in congenital hypogonadotropic hypogonadism. Genetics in Medicine, 22(11), 1759–1767. https://doi.org/10.1038/s41436-020-0896-0

3. Al Sayed, Y., & Howard, S. R. (2023). Panel testing for the molecular genetic diagnosis of congenital hypogonadotropic hypogonadism – a clinical perspective. European Journal of Human Genetics, 31(4), 387–394. https://doi.org/10.1038/s41431-022-01261-

4. Amato, Lorena Guimaraes Lima, Luciana Ribeiro Montenegro, Antonio Marcondes Lerario, Alexander Augusto Lima Jorge, Gil Guerra Junior, Caroline Schnoll, Alessandra Covallero Renck et al. "New genetic findings in a large cohort of congenital hypogonadotropic hypogonadism." European journal of endocrinology 181, no. 2 (2019): 103-119.

5. Arpitha, K. J. (2020). Transvaginal Ultrasound Diagnosis of Polycystic Ovarian Syndrome and its Correlation with Biochemical Parameters (Doctoral dissertation, Rajiv Gandhi University of Health Sciences (India).

6. Article, O. (2020). Clinical Pediatric. 31(1), 1–6. https://doi.org/10.1297/cpe.31.2021-0070

7. Barratt, C. L., Björndahl, L., De Jonge, C. J., Lamb, D. J., Osorio Martini, F., McLachlan, R., ... & Tournaye, H. (2017). The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance—challenges and future research Bollino, A., Cangiano, B., Goggi, G., Federici, S., Duminuco, P., Giovanelli, L., ... & Bonomi, M. (2020). Pubertal delay. The challenge of a timely differential diagnosis between congenital hypogonadotropic hypogonadism (CHH) and constitutional delay of growth and puberty (CDGP): a narrative review. Minerva Pediatrica, 72(4), 278-287.opportunities. Human reproduction update, 23(6), 660-680.

8. Butz, H., Nyírő, G., Kurucz, P. A., Likó, I., & Patócs, A. (2021). Molecular genetic diagnostics of hypogonadotropic hypogonadism: from panel design towards result interpretation in clinical practice. Human Genetics, 140(1), 113–134. https://doi.org/10.1007/s00439-020-02148-0

9. Cangiano, B., Swee, D. S., Quinton, R., & Bonomi, M. (2021). Genetics of congenital hypogonadotropic hypogonadism: peculiarities and phenotype of an oligogenic disease. In Human Genetics (Vol. 140, Issue 1). Springer Berlin Heidelberg. https://doi.org/10.1007/s00439-020-02147-1

10. Cangiano, B., Swee, D. S., Quinton, R., & Bonomi, M. (2021). Genetics of congenital hypogonadotropic hypogonadism: peculiarities and phenotype of an oligogenic disease. Human Genetics, 140(1), 77-111.

11. Cannarella, R., Gusmano, C., Condorelli, R. A., Bernini, A., Kaftalli, J., Maltese, P. E., Paolacci, S., Dautaj, A., Marceddu, G., Bertelli, M., La Vignera, S., & Calogero, A. E. (2023). Genetic Analysis of Patients with Congenital Hypogonadotropic Hypogonadism: A Case Series. International Journal of Molecular Sciences, 24(8), 1–17. https://doi.org/10.3390/ijms24087428

12. Dutta, S., Sengupta, P., & Muhamad, S. (2019). Male reproductive hormones and semen quality. Asian Pacific Journal of Reproduction, 8(5).

13. Festa, A., Umano, G. R., Miraglia del Giudice, E., & Grandone, A. (2020). Genetic Evaluation of Patients With Delayed Puberty and Congenital Hypogonadotropic Hypogonadism: Is it Worthy of Consideration? Frontiers in Endocrinology, 11(May), 1–11. https://doi.org/10.3389/fendo.2020.00253

14. Foran, D., Chen, R., Jayasena, C. N., Minhas, S., & Tharakan, T. (2023). The use of hormone stimulation in male infertility. Current Opinion in Pharmacology, 68, 102333. https://doi.org/10.1016/j.coph.2022.102333

15. Fraietta, R., Zylberstejn, D. S., & Esteves, S. C. (2013). Hypogonadotropic hypogonadism revisited. Clinics, 68(SUPPL. 1), 81–88. https://doi.org/10.6061/clinics/2013(Sup01)09

16. Gach, A., Pinkier, I., Sałacińska, K., Szarras-Czapnik, M., Salachna, D., Kucińska, A., & Sakowicz, A. (2020). Identification of gene variants in a cohort of hypogonadotropic hypogonadism: diagnostic utility of custom NGS panel and WES in unravelling genetic complexity of the disease. Molecular and Cellular Endocrinology, 517, 110968.

17. Gach, A., Pinkier, I., Wysocka, U., Sałacińska, K., Salachna, D., Szarras-Czapnik, M., Pietrzyk, A., Sakowicz, A., Nykel, A., Rutkowska, L., Rybak-Krzyszkowska, M., Socha, M., Jamsheer, A., & Jakubowski, L. (2022). New findings in oligogenic inheritance of congenital hypogonadotropic hypogonadism. Archives of Medical Science, 18(2), 353–364. https://doi.org/10.5114/aoms.2020.98909

18. Kathrins, M., & Niederberger, C. (2016). Diagnosis and treatment of infertility-related male hormonal dysfunction. Nature Reviews Urology, 13(6), 309-323.

19. Kokoreva, K. D., Chugunov, I. S., & Bezlepkina, O. B. (2021). Molecular genetics and phenotypic features of congenital isolated hypogonadotropic hypogonadism. Problemy Endokrinologii, 67(4), 46–56. https://doi.org/10.14341/probl12787

20. Lee, H. S., Shim, Y. S., & Hwang, J. S. (2022). Treatment of congenital hypogonadotropic hypo-gonadism in male patients. Annals of Pediatric Endocrinology and Metabolism, 27(3), 176–182. https://doi.org/10.6065/apem.2244208.104

21. Li, X., Guo, Y., Wang, X., Li, H., Mao, J., Yan, S., Luo, G., Wang, R., Wu, X., & Li, Y. (2023). Seminal plasma metabolomics signatures of normosmic congenital hypogonadotropic hypogonadism. Heliyon, 9(4), e14779. https://doi.org/10.1016/j.heliyon.2023.e14779

22. Liang, Y., Yang, X., Li, Y., Lei, L., Lan, Y., & Wang, S. (2023). Successful pregnancy and delivery after ovulation induction therapy in a woman with congenital hypogonadotropic hypogonadism: a case report. BMC Pregnancy and Childbirth, 23(1), 1–6. https://doi.org/10.1186/s12884-023-05682-7

23. Louden, E. D., Poch, A., Kim, H. G., Ben-Mahmoud, A., Kim, S. H., & Layman, L. C. (2021). Genetics of hypogonadotropic Hypogonadism—Human and mouse genes, inheritance, oligogenicity, and genetic counseling. Molecular and Cellular Endocrinology, 534, 111334. https://doi.org/10.1016/j.mce.2021.111334

24. Maione, L., Sarfati, J., Gonfroy-Leymarie, Cc. D. sign©lin., Salenave, S., Brailly-Tabard, S., Chanson, P., Trabado, Sc. D. sign©verin., Kaiser, U. B., & Young, J. (2022). Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study. Journal of Clinical Endocrinology and Metabolism, 107(7), E2812–E2824. https://doi.org/10.1210/clinem/dgac194

25. Messina, A., Pulli, K., Santini, S., Acierno, J., Känsäkoski, J., Cassatella, D., Xu, C., Casoni, F., Malone, S. A., Ternier, G., Conte, D., Sidis, Y., Tommiska, J., Vaaralahti, K., Dwyer, A., Gothilf, Y., Merlo, G. R., Santoni, F., Niederländer, N. J., … Pitteloud, N. (2020). Neuron-Derived Neurotrophic Factor Is Mutated in Congenital Hypogonadotropic Hypogonadism. American Journal of Human Genetics, 106(1), 58–70. https://doi.org/10.1016/j.ajhg.2019.12.003

26. Millar, A. C., Faghfoury, H., & Bieniek, J. M. (2021). Genetics of hypogonadotropic hypogonadism. Translational Andrology and Urology, 10(3), 1401–1409. https://doi.org/10.21037/tau.2020.03.33

27. Miraoui, H., Dwyer, A. A., Sykiotis, G. P., Plummer, L., Chung, W., Feng, B., Beenken, A., Clarke, J., Pers, T. H., Dworzynski, P., Keefe, K., Niedziela, M., Raivio, T., Crowley, W. F., Seminara, S. B., Quinton, R., Hughes, V. A., Kumanov, P., Young, J., … Pitteloud, N. (2013). Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. American Journal of Human Genetics, 92(5), 725–743. https://doi.org/10.1016/j.ajhg.2013.04.008

28. Moalla, M., Hadj Kacem, F., Al-Mutery, A. F., Mahfood, M., Mejdoub-Rekik, N., Abid, M., Mnif-Feki, M., & Hadj Kacem, H. (2019). Nonstop mutation in the Kisspeptin 1 receptor (KISS1R) gene causes normosmic congenital hypogonadotropic hypogonadism. Journal of Assisted Reproduction and Genetics, 36(6), 1273–1280. https://doi.org/10.1007/s10815-019-01468-z

29. Naushad, A., & Kalra, P. (2022). Abstract 119: Neuron derived neurotropic factor- A novel gene implicated in congenital hypogonadotropic hypogonadism. Indian Journal of Endocrinology and Metabolism, 26(8), 51. https://doi.org/10.4103/2230-8210.363623

30. Neocleous, V., Fanis, P., Toumba, M., Tanteles, G. A., Schiza, M., Cinarli, F., Nicolaides, N. C., Oulas, A., Spyrou, G. M., Mantzoros, C. S., Vlachakis, D., Skordis, N., & Phylactou, L. A. (2020). GnRH Deficient Patients With Congenital Hypogonadotropic Hypogonadism: Novel Genetic Findings in ANOS1, RNF216, WDR11, FGFR1, CHD7, and POLR3A Genes in a Case Series and Review of the Literature. Frontiers in Endocrinology, 11(August). https://doi.org/10.3389/fendo.2020.00626

31. Oleari, R., Massa, V., Cariboni, A., & Lettieri, A. (2021). The differential roles for neurodevelopmental and neuroendocrine genes in shaping GnRH neuron physiology and deficiency. International Journal of Molecular Sciences, 22(17), 9425.

32. Ortiz-Cabrera, N. V., Gavela-Pérez, T., Mejorado-Molano, F. J., Santillán-Coello, J. M., Villacampa-Aubá, J. M., Trujillo-Tiebas, M. J., & Soriano-Guillén, L. (2022). Diagnostic yield of clinical exome sequencing in congenital hypogonadotropic hypogonadism considering the degree of olfactory impairment. Anales de Pediatría (English Edition), 97(4), 247–254. https://doi.org/10.1016/j.anpede.2021.06.003

33. Pitteloud N, et al. Congenital hypogonadotropic hypogonadism:insight into the idiopathic form .Nat Rev Endocrine. 2019;15(10):610-628

34. Swee, D. S., & Quinton, R. (2019). Managing congenital hypogonadotrophic hypogonadism: a contemporary approach directed at optimizing fertility and long-term outcomes in males. Therapeutic advances in endocrinology and metabolism, 10, 2042018819826889.

35. Saleem, M., Khan, S. A., Khan, M. M. M., Suchal, Z. A., & Ram, N. (2023). Clinical and Biochemical Characteristics of Male Idiopathic Hypogonadotropic Hypogonadism Patients: A Retrospective Cross Sectional Study. International Journal of Fertility and Sterility, 17(1), 57–60. https://doi.org/10.22074/IJFS.2022.540499.1201

36. Šmigoc Schweiger, D., Davidović Povše, M., Trebušak Podkrajšek, K., Battelino, T., & Avbelj Stefanija, M. (2022). GNRHR-related central hypogonadism with spontaneous recovery – case report. Italian Journal of Pediatrics, 48(1), 1–5. https://doi.org/10.1186/s13052-022-01377-5

37. Stuckey, B. G. A., Jones, T. W., Ward, B. K., & Wilson, S. G. (2023). Digenic Congenital Hypogonadotropic Hypogonadism Due to Heterozygous GNRH1 p.R31C and AMHR2 p.G445_L453del Variants. Genes, 14(6). https://doi.org/10.3390/genes14061204

38. Sugiarto, A. M., & Soelistijo, S. A. (2022). A female with isolated hypogonadotropic hypogonadism: A case report and review article. Annals of Medicine and Surgery, 74(6), 103289. https://doi.org/10.1016/j.amsu.2022.103289

39. Swee, D. S., & Quinton, R. (2022). Current concepts surrounding neonatal hormone therapy for boys with congenital hypogonadotropic hypogonadism. Expert Review of Endocrinology and Metabolism, 17(1), 47–61. https://doi.org/10.1080/17446651.2022.2023008

40. Sharma, A., Minhas, S., Dhillo, W. S., & Jayasena, C. N. (2021). Male infertility due to testicular disorders. The Journal of Clinical Endocrinology & Metabolism, 106(2), e442-e459.

41. Takashima, A., Yagi, S., Yamaguchi, K., Kurahashi, K., Kojima, Y., Zheng, R., Ise, T., Kusunose, K., Yoshida, S., Yamada, H., Soeki, T., Wakatsuki, T., Aihara, K. I., Akaike, M., & Sata, M. (2021). Congenital hypogonadotropic hypogonadism with early-onset coronary artery disease. Journal of Medical Investigation, 68(1.2), 189–191. https://doi.org/10.2152/jmi.68.189

42. Tamaoka, S., Suzuki, E., Hattori, A., Ogata, T., Fukami, M., & Katoh-Fukui, Y. (2021). NDNF variants are rare in patients with congenital hypogonadotropic hypogonadism. Human Genome Variation, 8(1), 4–6. https://doi.org/10.1038/s41439-021-00137-x

43. Tang, R., Liu, X., Peng, Y., Ju, W., Hao, W., Peng, X., & Chen, R. (2020). Nectin-like molecule 2, a necessary sexual maturation regulator, participates in congenital hypogonadotropic hypogonadism. Gene, 754(June), 144885. https://doi.org/10.1016/j.gene.2020.144885

44. Winters, S. J. (2022). Congenital Hypogonadotropic Hypogonadism. A Case-Based Guide to Clinical Endocrinology, Third Edition, 1, 275–287. https://doi.org/10.1007/978-3-030-84367-0_31

45. Xu, C., Cassatella, D., van der Sloot, A. M., Quinton, R., Hauschild, M., De Geyter, C., Flück, C., Feller, K., Bartholdi, D., Nemeth, A., Halperin, I., Pekic Djurdjevic, S., Maeder, P., Papadakis, G., Dwyer, A. A., Marino, L., Favre, L., Pignatelli, D., Niederländer, N. J., … Pitteloud, N. (2018). Evaluating CHARGE syndrome in congenital hypogonadotropic hypogonadism patients harboring CHD7 variants. Genetics in Medicine, 20(8), 872–881. https://doi.org/10.1038/gim.2017.197

46. Xu, C., & Pitteloud, N. (2019). Congenital Hypogonadotropic Hypogonadism (Isolated GnRH Deficiency). Contemporary Endocrinology, 229–250. https://doi.org/10.1007/978-3-030-11339-1_12

47. Young, J., Xu, C., Papadakis, G. E., Acierno, J. S., Maione, L., Hietamäki, J., ... & Pitteloud, N. (2019). Clinical management of congenital hypogonadotropic hypogonadism. Endocrine reviews, 40(2), 669-710.

48. Yu, B., Chen, K., Mao, J., Hou, B., You, H., Wang, X., Nie, M., Huang, Q., Zhang, R., Zhu, Y., Sun, B., Feng, F., Zhou, W., & Wu, X. (2022). The diagnostic value of the olfactory evaluation for congenital hypogonadotropic hypogonadism. Frontiers in Endocrinology, 13(September), 1–10. https://doi.org/10.3389/fendo.2022.909623

49. Zhang, L., Gao, Y., Du, Q., Liu, L., Li, Y., Dey, S. K., & Liao, Z. (2021). Genetic profiles and three-year follow-up study of Chinese males with congenital hypogonadotropic hypogonadism. The journal of sexual medicine, 18(9), 1500-1510.